Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT

Aclidinium/formoterol 400/12 µg is a twice-daily maintenance bronchodilator for COPD. This post hoc study evaluated aclidinium/formoterol vs aclidinium 400 µg, formoterol 12 µg, or placebo in patient subgroups. Data were pooled from two 24-week Phase III clinical trials (ACLIFORM and AUGMENT). Patie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of chronic obstructive pulmonary disease 2019, Vol.14, p.479-491
Hauptverfasser:	D'Urzo, Anthony D, Singh, Dave, Donohue, James F, Kerwin, Edward M, Ribera, Anna, Molins, Eduard, Chuecos, Ferran, Jarreta, Diana, Gil, Esther Garcia
Format:	Artikel
Sprache:	eng
Schlagworte:	aclidinium Administration, Inhalation Adrenergic beta-2 Receptor Agonists - administration & dosage Adrenergic beta-2 Receptor Agonists - adverse effects Age Age Factors Aged Bronchodilator Agents - administration & dosage Bronchodilator Agents - adverse effects Chronic obstructive pulmonary disease Clinical medicine Clinical trials Clinical Trials, Phase III as Topic COPD Demographics Disease Progression Drug Combinations Drug dosages Dyspnea Female Forced Expiratory Volume formoterol Formoterol Fumarate - administration & dosage Formoterol Fumarate - adverse effects Humans Lung - drug effects Lung - physiopathology Lung diseases Male Middle Aged Multicenter Studies as Topic Muscarinic Antagonists - administration & dosage Muscarinic Antagonists - adverse effects Original Research Patients Pulmonary Disease, Chronic Obstructive - diagnosis Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary Disease, Chronic Obstructive - physiopathology Randomized Controlled Trials as Topic Recovery of Function Severity of Illness Index Sex Factors Time Factors Treatment Outcome Tropanes - administration & dosage Tropanes - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aclidinium/formoterol 400/12 µg is a twice-daily maintenance bronchodilator for COPD. This post hoc study evaluated aclidinium/formoterol vs aclidinium 400 µg, formoterol 12 µg, or placebo in patient subgroups. Data were pooled from two 24-week Phase III clinical trials (ACLIFORM and AUGMENT). Patients (N=3,394) were analyzed by baseline airflow obstruction severity (moderate/severe), age (
ISSN:	1178-2005 1176-9106 1178-2005
DOI:	10.2147/COPD.S185502